|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dholaria B, Hammond W, Shreders A and Lou
Y: Emerging therapeutic agents for lung cancer. J Hematol Oncol.
9:1382016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Alì G, Donati V, Loggini B, Servadio A,
Dell'Omodarme M, Prati MC, Camacci T, Lucchi M, Melfi F, Mussi A,
et al: Different estrogen receptor beta expression in distinct
histologic subtypes of lung adenocarcinoma. Hum Pathol.
39:1465–1473. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gasperino J: Gender is a risk factor for
lung cancer. Med Hypotheses. 76:328–331. 2011. View Article : Google Scholar
|
|
5
|
Schwartz AG, Prysak GM, Murphy V, Lonardo
F, Pass H, Schwartz J and Brooks S: Nuclear estrogen receptor beta
in lung cancer: Expression and survival differences by sex. Clin
Cancer Res. 11:7280–7287. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wakelee HA, Chang ET, Gomez SL, Keegan TH,
Feskanich D, Clarke CA, Holmberg L, Yong LC, Kolonel LN, Gould MK,
et al: Lung cancer incidence in never smokers. J Clin Oncol.
25:472–478. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Papadopoulos A, Guida F, Leffondré K,
Cénée S, Cyr D, Schmaus A, Radoï L, Paget Bailly S, Carton M,
Menvielle G, et al: Heavy smoking and lung cancer: Are women at
higher risk? Result of the ICARE study. Br J Cancer. 110:1385–1391.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ryu JS, Jeon SH, Kim JS, Lee JH, Kim SH,
Hong JT, Jeong JH, Jeong JJ, Lee MD, Min SJ, et al: Gender
differences in susceptibility to smoking among patients with lung
cancer. Korean J Intern Med (Korean Assoc Intern Med). 26:427–431.
2011.
|
|
9
|
Guo H, Huang K, Zhang X, Zhang W, Guan L,
Kuang D, Deng Q, Deng H, Zhang X, He M, et al: Women are more
susceptible than men to oxidative stress and chromosome damage
caused by polycyclic aromatic hydrocarbons exposure. Environ Mol
Mutagen. 55:472–481. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Spivack SD, Hurteau GJ, Reilly AA, Aldous
KM, Ding X and Kaminsky LS: CYP1B1 expression in human lung. Drug
Metab Dispos. 29:916–922. 2001.PubMed/NCBI
|
|
11
|
Cavalieri E, Chakravarti D, Guttenplan J,
et al: Catechol estrogen quinones as initiators of breast and other
human cancers: Implications for biomarkers of susceptibility and
cancer prevention. Biochim Biophys Acta. 1766:63–78.
2006.PubMed/NCBI
|
|
12
|
Belous AR, Hachey DL, Dawling S, Roodi N
and Parl FF: Cytochrome P450 1B1 mediated estrogen metabolism
results in estrogen deoxyribonucleoside adduct formation. Cancer
Res. 67:812–817. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Siegfried JM, Hershberger PA and Stabile
LP: Estrogen receptor signaling in lung cancer. Semin Oncol.
36:524–531. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lienert T, Serke M, Schönfeld N and
Loddenkemper R: Lung cancer in young females. Eur Respir J.
16:986–990. 2000. View Article : Google Scholar
|
|
15
|
Ross H, Oldham FB, Bandstra B, Sandalic L,
Bianco J, Bonomi P and Singer JW: Serum free estradiol (E2) levels
are prognostic in men with chemotherapy naive advanced non small
cell lung cancer (NSCLC) and performance status (PS) 2. J Clin
Oncol. (Suppl 18)25:76832007. View Article : Google Scholar
|
|
16
|
Chan YX, Alfonso H, Chubb SAP, Handelsman
DJ, Fegan PG, Hankey GJ, Golledge J, Flicker L and Yeap BB: Higher
Dihydrotestosterone Is Associated with the Incidence of Lung Cancer
in Older Men. Horm Cancer. 8:119–126. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stabile LP, Davis AL, Gubish CT, Hopkins
TM, Luketich JD, Christie N, Finkelstein S and Siegfried JM: Human
non-small cell lung tumors and cells derived from normal lung
express both estrogen receptor alpha and beta and show biological
responses to estrogen. Cancer Res. 62:2141–2150. 2002.PubMed/NCBI
|
|
18
|
Márquez-Garbán DC, Chen HW, Fishbein MC,
Goodglick L and Pietras RJ: Estrogen receptor signaling pathways in
human non small cell lung cancer. Steroids. 72:135–143. 2007.
View Article : Google Scholar
|
|
19
|
Fasco MJ, Hurteau GJ and Spivack SD:
Gender-dependent expression of alpha and beta estrogen receptors in
human nontumor and tumor lung tissue. Mol Cell Endocrinol.
188:125–140. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jala VR, Radde BN, Haribabu B and Klinge
CM: Enhanced expression of G protein coupled estrogen receptor
(GPER/GPR30) in lung cancer. BMC Cancer. 12:6242012. View Article : Google Scholar
|
|
21
|
Liu C, Liao Y, Fan S, Tang H, Jiang Z,
Zhou B, Xiong J, Zhou S, Zou M and Wang J: G protein coupled
estrogen receptor (GPER) mediates NSCLC progression induced by 17β
estradiol (E2) and selective agonist G1. Med Oncol. 32:1042015.
View Article : Google Scholar
|
|
22
|
Słowikowski BK, Lianeri M and Jagodziński
PP: Exploring estrogenic activity in lung cancer. Mol Biol Rep.
44:35–50. 2017. View Article : Google Scholar
|
|
23
|
Hsu LH, Chu NM and Kao SH: Estrogen,
Estrogen Receptor and Lung Cancer. Int J Mol Sci. 18:17132017.
View Article : Google Scholar :
|
|
24
|
Zhang G, Liu X, Farkas AM, Parwani AV,
Lathrop KL, Lenzner D, Land SR and Srinivas H: Estrogen receptor
beta functions through nongenomic mechanisms in lung cancer cells.
Mol Endocrinol. 23:146–156. 2009. View Article : Google Scholar
|
|
25
|
Hershberger PA, Stabile LP, Kanterewicz B,
Rothstein ME, Gubish CT, Land S, Shuai Y, Siegfried JM and Nichols
M: Estrogen receptor beta (ERbeta) subtype specific ligands
increase transcription, p44/p42 mitogen activated protein kinase
(MAPK) activation and growth in human non small cell lung cancer
cells. J Steroid Biochem Mol Biol. 116:102–109. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fan S, Liao Y, Liu C, Huang Q, Liang H, Ai
B, Fu S and Zhou S: Estrogen promotes tumor metastasis via estrogen
receptor beta mediated regulation of matrix metalloproteinase 2 in
non-small cell lung cancer. Oncotarget. 8:56443–56459.
2017.PubMed/NCBI
|
|
27
|
Liu C, Liao Y, Fan S, Fu X, Xiong J, Zhou
S, Zou M and Wang J: G Protein Coupled Estrogen Receptor Antagonist
G15 Decreases Estrogen Induced Development of Non Small Cell Lung
Cancer. Oncol Res. 27:283–292. 2019. View Article : Google Scholar
|
|
28
|
Luu The V: Assessment of steroidogenesis
and steroidogenic enzyme functions. J Steroid Biochem Mol Biol.
137:176–182. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Labrie F: All sex steroids are made
intracellularly in peripheral tissues by the mechanisms of
intracrinology after menopause. J Steroid Biochem Mol Biol.
145:133–138. 2015. View Article : Google Scholar
|
|
30
|
Provost PR, Blomquist CH, Drolet R,
Flamand N and Tremblay Y: Androgen inactivation in human lung
fibroblasts: Variations in levels of 17 beta hydroxysteroid
dehydrogenase type 2 and 5 alpha reductase activity compatible with
androgen inactivation. J Clin Endocrinol Metab. 87:3883–3892.
2002.PubMed/NCBI
|
|
31
|
Niikawa H, Suzuki T, Miki Y, Suzuki S,
Nagasaki S, Akahira J, Honma S, Evans DB, Hayashi S, Kondo T, et
al: Intratumoral estrogens and estrogen receptors in human non
small cell lung carcinoma. Clin Cancer Res. 14:4417–4426. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Verma MK, Miki Y and Sasano H: Aromatase
in human lung carcinoma. Steroids. 76:759–764. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Verma MK, Miki Y, Abe K, Suzuki T, Niikawa
H, Suzuki S, Kondo T and Sasano H: Intratumoral localization and
activity of 17β hydroxysteroid dehydrogenase type 1 in non small
cell lung cancer: A potent prognostic factor. J Transl Med.
11:1672013. View Article : Google Scholar
|
|
34
|
Drzewiecka H and Jagodzinski PP:
Conversion of estrone to 17 beta estradiol in human non small cell
lung cancer cells in vitro. Biomed Pharmacother. 66:530–534. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Drzewiecka H, Gałęcki B,
Jarmołowska-Jurczyszyn D, Kluk A, Dyszkiewicz W and Jagodziński PP:
Increased expression of 17 beta hydroxysteroid dehydrogenase type 1
in non small cell lung cancer. Lung Cancer. 87:107–116. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Miettinen MM, Mustonen MV, Poutanen MH,
Isomaa VV and Vihko RK: Human 17 beta-hydroxysteroid dehydrogenase
type 1 and type 2 isoenzymes have opposite activities in cultured
cells and characteristic cell and tissue specific expression.
Biochem J. 314(Pt 3): 839–845. 1996. View Article : Google Scholar
|
|
37
|
Vihko P, Isomaa V and Ghosh D: Structure
and function of 17beta hydroxysteroid dehydrogenase type 1 and type
2. Mol Cell Endocrinol. 171:71–76. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Goldstraw P, Crowley J, Chansky K, Giroux
DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L;
International Association for the Study of Lung Cancer
International Staging Committee Participating Institutions: The
IASLC Lung Cancer Staging Project: Proposals for the revision of
the TNM stage groupings in the forthcoming (seventh) edition of the
TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Győrffy B, Surowiak P, Budczies J and
Lánczky A: Online survival analysis software to assess the
prognostic value of biomarkers using transcriptomic data in
non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar
|
|
40
|
Tellmann G: The E Method: A highly
accurate technique for gene expression analysis. Nat Methods.
3:i–ii. 2006. View Article : Google Scholar
|
|
41
|
Drzewiecka H, Gałęcki B,
Jarmołowska-Jurczyszyn D, Kluk A, Dyszkiewicz W and Jagodziński
PPPP: Decreased expression of connective tissue growth factor in
non small cell lung cancer is associated with clinicopathological
variables and can be restored by epigenetic modifiers. J Cancer Res
Clin Oncol. 142:1927–1946. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Burns TF and Stabile LP: Targeting the
estrogen pathway for the treatment and prevention of lung cancer.
Lung Cancer Manag. 3:43–52. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ivanova MM, Mazhawidza W, Dougherty SM and
Klinge CM: Sex differences in estrogen receptor subcellular
location and activity in lung adenocarcinoma cells. Am J Respir
Cell Mol Biol. 42:320–330. 2010. View Article : Google Scholar :
|
|
44
|
Hammoud Z, Tan B, Badve S and Bigsby RM:
Estrogen promotes tumor progression in a genetically defined mouse
model of lung adenocarcinoma. Endocr Relat Cancer. 15:475–483.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hilborn E, Stål O, Alexeyenko A and
Jansson A: The regulation of hydroxysteroid 17β dehydrogenase type
1 and 2 gene expression in breast cancer cell lines by estradiol,
dihydrotestosterone, microRNAs, and genes related to breast cancer.
Oncotarget. 8:62183–62194. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lewis Wambi JS and Jordan VC: Estrogen
regulation of apoptosis: How can one hormone stimulate and inhibit?
Breast Cancer Res. 11:2062009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Speirs V, Green AR, Walton DS, Kerin MJ,
Fox JN, Carleton PJ, Desai SB and Atkin SL: Short-term primary
culture of epithelial cells derived from human breast tumours. Br J
Cancer. 78:1421–1429. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hilborn E, Stål O and Jansson A: Estrogen
and androgen converting enzymes 17β hydroxysteroid dehydrogenase
and their involvement in cancer: With a special focus on 17β
hydroxysteroid dehydrogenase type 1, 2, and breast cancer.
Oncotarget. 8:30552–30562. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Miyoshi Y, Ando A, Shiba E, Taguchi T,
Tamaki Y and Noguchi S: Involvement of up regulation of 17beta
hydroxys teroid dehydrogenase type 1 in maintenance of intratumoral
high estradiol levels in postmenopausal breast cancers. Int J
Cancer. 94:685–689. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang CYY, Chen J, Yin DCC and Lin SXX:
The contri bution of 17beta hydroxysteroid dehydrogenase type 1 to
the estradiol estrone ratio in estrogen sensitive breast cancer
cells. PLoS One. 7:e298352012. View Article : Google Scholar
|
|
51
|
Gunnarsson C, Olsson BM and Stål O;
Southeast Sweden Breast Cancer Group: Abnormal expression of 17beta
hydroxysteroid dehydrogenases in breast cancer predicts late
recurrence. Cancer Res. 61:8448–8451. 2001.PubMed/NCBI
|
|
52
|
Gunnarsson C, Hellqvist E and Stål O:
17beta Hydroxysteroid dehydrogenases involved in local oestrogen
synthesis have prog nostic significance in breast cancer. Br J
Cancer. 92:547–552. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Han B, Li S, Song D, Poisson Paré D, Liu
G, Luu The V, Ouellet J, Li S, Labrie F and Pelletier G: Expression
of 17β hydroxysteroid dehydrogenase type 2 and type 5 in breast
cancer and adjacent non malignant tissue: A correlation to
clinicopathological parameters. J Steroid Biochem Mol Biol.
112:194–200. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wang CT, Li CFCC, Wu WJ, Huang CN, Li CC,
Li WM, Chan TC, Liang PI, Hsing CH and Liao KM: High Expression of
17β hydroxysteroid Dehydrogenase Type 2 is Associated with a Better
Prognosis in Urothelial Carcinoma of the Urinary Tract. J Cancer.
7:2221–2230. 2016. View Article : Google Scholar :
|
|
55
|
Frycz BA, Murawa D, Borejsza-Wysocki M,
Marciniak R, Murawa P, Drews M and Jagodziński PP: Expression of
17β hydroxysteroid dehydrogenase type 2 is associated with some
clinicopathological features in gastric cancer. Biomed
Pharmacother. 70:24–27. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lee YE, He HL, Shiue YL, Lee SW, Lin LC,
Wu TF, Chang IW, Lee HH and Li CF: The prognostic impact of lipid
biosyn thesis-associated markers, HSD17B2 and HMGCS2, in rectal
cancer treated with neoadjuvant concurrent chemoradiotherapy.
Tumour Biol. 36:7675–7683. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Marino M: Xenoestrogens challenge 17β
estradiol protective effects in colon cancer. World J Gastrointest
Oncol. 6:67–73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Cornel KMC, Krakstad C, Delvoux B,
Xanthoulea S, Jori B, Bongers MY, Konings GF, Kooreman LF,
Kruitwagen RF, Salvesen HB, et al ENITEC: High mRNA levels of 17β
hydroxysteroid dehydrogenase type 1 correlate with poor prognosis
in endometrial cancer. Mol Cell Endocrinol. 442:51–57. 2017.
View Article : Google Scholar
|
|
59
|
Jeong Y, Xie Y, Lee W, Bookout AL, Girard
L, Raso G, Behrens C, Wistuba II, Gadzar AF, Minna JD, et al:
Research resource: Diagnostic and therapeutic potential of nuclear
receptor expression in lung cancer. Mol Endocrinol. 26:1443–1454.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Recchia AG, Musti AM, Lanzino M, Panno ML,
Turano E, Zumpano R, Belfiore A, Andò S and Maggiolini M: A
cross-talk between the androgen receptor and the epidermal growth
factor receptor leads to p38MAPK dependent activation of mTOR and
cyclinD1 expression in prostate and lung cancer cells. Int J
Biochem Cell Biol. 41:603–614. 2009. View Article : Google Scholar
|
|
61
|
Harlos C, Musto G, Lambert P, Ahmed R and
Pitz MW: Androgen pathway manipulation and survival in patients
with lung cancer. Horm Cancer. 6:120–127. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Huuskonen P, Amezaga MR, Bellingham M,
Jones LH, Storvik M, Häkkinen M, Keski-Nisula L, Heinonen S,
O'Shaughnessy PJ, Fowler PA, et al: The human placental proteome is
affected by maternal smoking. Reprod Toxicol. 63:22–31. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ito K, Suzuki T, Moriya T, Utsunomiya H,
Sugawara A, Konno R, Sato S and Sasano H: Retinoid receptors in the
human endometrium and its disorders: A possible modulator of 17 β
hydroxysteroid dehydrogenase. J Clin Endocrinol Metab.
86:2721–2727. 2001.PubMed/NCBI
|
|
64
|
Reed MJ, Rea D, Duncan LJ and Parker MG:
Regulation of estradiol 17 beta hydroxysteroid dehydrogenase
expression and activity by retinoic acid in T47D breast cancer
cells. Endocrinology. 135:4–9. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Su EJ, Cheng YH, Chatterton RT, Lin ZH,
Yin P, Reierstad S, Innes J and Bulun SE: Regulation of 17 beta
hydroxysteroid dehydrogenase type 2 in human placental endothelial
cells. Biol Reprod. 77:517–525. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Li Y, Lu DG, Ma YM and Liu H: Association
between Retinoic acid receptor β hypermethylation and NSCLC risk: A
meta analysis and literature review. Oncotarget. 8:5814–5822.
2017.
|
|
67
|
Muñiz Hernández S, Huerta Yepez S,
Hernández Pedro N, Ramírez Tirado LA, Aviles Salas A, Maldonado A,
Hernández Cueto D, Baay Guzmán G and Arrieta O: Association between
nuclear expression of retinoic acid receptor alpha and beta and
clinicopathological features and prognosis of advanced non small
cell lung cancer. Int J Clin Oncol. 21:1051–1061. 2016. View Article : Google Scholar
|
|
68
|
Elo JP, Härkönen P, Kyllönen AP,
Lukkarinen O and Vihko P: Three independently deleted regions at
chromosome arm 16q in human prostate cancer: Allelic loss at
16q24.1 q24.2 is associated with aggressive behaviour of the
disease, recurrent growth, poor differentiation of the tumour and
poor prognosis for the patient. Br J Cancer. 79:156–160. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Jansson A: 17Beta hydroxysteroid
dehydrogenase enzymes and breast cancer. J Steroid Biochem Mol
Biol. 114:64–67. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Sato M, Mori Y, Sakurada A, Fukushige S,
Ishikawa Y, Tsuchiya E, Saito Y, Nukiwa T, Fujimura S and Horii A:
Identification of a 910-kb region of common allelic loss in
chromosome bands 16q24.1 q24.2 in human lung cancer. Genes
Chromosomes Cancer. 22:1–8. 1998. View Article : Google Scholar : PubMed/NCBI
|
